Exact Sciences post positive results from MRD trial (Clinical Trials Arena)

Exact Sciences has released promising results from its trial of the Oncodetect test, designed to identify molecular residual disease (MRD) via circulating tumor DNA (ctDNA) detection post-cancer treatment. The Alpha-CORRECT study revealed the test achieved 78% sensitivity and 80% specificity in post-surgical checks, rising to 91% sensitivity and 94% specificity during surveillance monitoring. Powered by whole exome sequencing, Oncodetect aims to fill the critical need for accurate MRD monitoring, especially in colorectal cancer.